Status | Study |
Recruiting |
Study Name: Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Condition: Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Adenocarcinoma Date: 2016-03-30 Interventions: Drug: Copanlisib Given IV |
Recruiting |
Study Name: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2016-03-15 Interventions: Drug: Carboplatin Given IV |
Recruiting |
Study Name: Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: High Grade Ovarian Serous Adenocarcinoma Ovarian Endometrioid Tumor Date: 2015-12-09 Interventions: Drug: ATR Kinase Inhibitor VX-970 |
Withdrawn |
Study Name: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Condition: Adult Solid Neoplasm Estrogen Receptor Negative Fallopian Date: 2015-12-09 Interventions: Drug: Hsp90 Inhibitor AT13387 |
Recruiting |
Study Name: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2015-07-17 Interventions: Drug: Cediranib Maleate Given |
Recruiting |
Study Name: Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Condition: Endometrial Clear Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Date: 2015-07-09 Interventions: Drug: Cisplatin Given IV |
Recruiting |
Study Name: A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Condition: HER2/Neu+ Uterine Serous Carcinoma Date: 2015-07-02 Interventions: Drug: Afatinib Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 |
Recruiting |
Study Name: Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions Condition: Pancreatic Cysts Pancreatic Mucinous-Cystic Neoplasm Intra Date: 2015-06-23 Interventions: Procedure: Endoscopic ultrasound guided needle based confocal endomicroscopy Needle based confocal laser |
Recruiting |
Study Name: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis Condition: Cancer Date: 2015-04-14 Interventions: Drug: systemic chemotherapy twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks af |
Recruiting |
Study Name: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Condition: Fallopian Tube Transitional Cell Carcinoma Malignant Ovarian Clear Cell Tumor Date: 2015-02-10 Interventions: Drug: Gemcitabine Hydrochloride |